Hematologic and metabolic effects of dietary supplementation with Agaricus sylvaticus fungi on rats bearing solid walker 256 tumor

Experimental Biology and Medicine

Volumn 233, Issue 11, 2008, Pages 1341-1347

  Taveira, Vanessa Cunha ^a   Novaes, Maria Rita Carvalho Garbi ^a   Reis, Marcelo Dos Anjos ^b   Da Silva, Monique Fernandes ^b  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b University of Brasilia ^*

Author keywords

Agaricus sylvaticus; Anemia; Biochemical parameters; Experimental cancer

Indexed keywords

AGARICUS SYLVATICUS EXTRACT; ALANINE; ARGININE; ASPARTIC ACID; BETA GLUCAN; C REACTIVE PROTEIN; CREATININE; ERGOSTEROL; GLUCOSE; GLUTAMIC ACID; GLYCINE; HEMOGLOBIN; HISTIDINE; LEUCINE; LIPID; LYSINE; METHIONINE; PHENYLALANINE; PLACEBO; PLANT EXTRACT; PROLINE; PROTEIN DERIVATIVE; SERINE; THREONINE; TRIACYLGLYCEROL; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VALINE;

AGARICUS SYLVATICUS; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE COUNT; EXPERIMENTAL RAT; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; INOCULATION; LEUKOCYTE COUNT; MALE; MUSHROOM; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SOLID TUMOR; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; WALKER CARCINOMA; AGARICUS; ANIMAL; BLOOD; BLOOD ANALYSIS; BLOOD EXAMINATION; CARCINOMA; METABOLISM;

AGARICUS SYLVATICUS; ANIMALIA; BASIDIOMYCOTA; FUNGI; RATTUS;

AGARICUS; ANEMIA; ANIMALS; BLOOD CHEMICAL ANALYSIS; CARCINOMA 256, WALKER; DIETARY SUPPLEMENTS; HEMATOLOGIC TESTS; MALE; RATS;

EID: 58249093735     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0803-RM-107     Document Type: Article

References (43)

1. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia and the cancer patient. Int J Radiat Oncol Biol Phys 63:25-36, 2005.
2. Jin M, Jeon H, Jung HJ, Kim B, Shin SS, Choi JJ, Lee JK, Kang CY, Kim S. Enhancement of repopulation and hematopoiesis of bone marrow cells in irradiated mice by oral administration of PG 101, a water soluble extract from Lentinus lepideus. Exp Biol Med 228:759-766, 2003.
3. Hamamoto T, Suzuki K, Sasaki H, Ichikawa M, Kodama S, Watanabe M. Differences in effects of oncogenes on sensitivity to anticancer drugs. J Radiat Res 46:197-203, 2005.
4. Quemener V, Bansard JY, Delamaire M, Roth S, Havouis R, Desury D, Moulinoux JP. Red blood cell polyamines, anemia and tumor growth in the rat. Eur J Cancer 32A:316-322, 1996.
5. Savonije JH, Van Groenijen CJV, Wormhoudt LW, Giaconne J. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 11:206-216, 2006.
6. Klein S, Luu K, Sakurai Y, Miller R, Larger M, Zhang XJ. Metabolic response to radiation therapy in patients with cancer. Metabolism 45:767-773, 1996.
7. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 80:1107-1213, 2000.
8. Lattermann R, Geisser W, Georgieff M, Wachter U, Goertz A, Gnann R, Schrincker T. Integrated analysis of glucose, lipid and urea metabolism in patients with bladder cancer: impact of tumor stage. Nutrition 19:589-592, 2003.
9. Helzlsouer KJ, Erlinger TP, Platz EA. C-Reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study.Eur J Cancer 42:704-707, 2006.
10. Deegan O, Walshe K, Kavanagh K, Doyle S. Quantitative detection of C-reactive protein using phosphocoline-labeled enzyme or micro- spheres. Analyt Biochem 312:175-181, 2003.
11. Lehrer S, Diamond EJ, Mamkine B, Drolle MJ, Stone NN, Stock RG. C-Reactive protein is significantly associated with prostate specific antigen and metastatic disease in prostate cancer. BJU Int 95:961-962,2005.
12. Nikiteas NI, Tzanakis N, Gazouli M, Rallis J, Daniilidis K, Theodoropoulos G, Kostakis A, Peros G. Serum IL-6, TNF-α and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11:1639-1643, 2005.
13. Barbisan LF, Scolastici C, Miyamota M, Salvadori DMF, Ribeiro LR, Eira AF, Camargo JLV. Effects of crude extracts of Agaricus blazei on DNA damage and on rat liver carcinogenesis induced by diethylnitros-amine. Genet Molec Res 2:295-308, 2003.
14. Sullivan R, Smith JE, Rowan NJ. Medicinal mushrooms and cancer therapy: translating a traditional practice to Western medicine. Perspect Biol Med 49:159-170, 2006.
15. Novaes MRCG, Novaes LCG, Recova V, Melo A. Evaluation of acute toxicity of edible mushroom Agaricus sylvaticus. Clin Nutr 14:672-673,2005.
16. Cao LZ, Lin ZB. Regulatory effect of Ganoderma lucidum poly-saccharides on cytotoxic T-lymphocytes induced by dendritic cells in vitro. Acta Pharmacol Sin 24:312-326, 2003.
17. Brown GD, Gordon S. Fungal β-glucans and mammalian immunity. Immunity 1:311-315, 2003.
18. Novaes MRCG, Pantaleão C. Pharmacological effects of nutritional supplementation of arginine in gastrointestinal cancer patients. Brazil J Clin Nutr 19:26-31, 2004.
19. Wang H, Ng TB. Isolation of a novel N-acetylglucosamine-specific lectin from fresh sclerotinia of the edible mushroom Pleurotus tuber-regium. Protein Expr Purif 29:156-160, 2003.
20. Dias ES, Abe C, Schwan RF. Truths and myths about the mushroom Agaricus blazei. Sci Agric 61:545-549, 2004.
21. Ouden M, Ubachs JMH, Stoot JEGM, Wersch JWJ. Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumors. Eur J Obstet Gynecol 72:73-77, 1997.
22. Vido AA, Cavalcanti TC, Guimaraes F, Vieira-Matos NA, Retori O. Hemolytic component of cancer anemia: effects of osmotic and metabolic stress on the erythrocytes of rats bearing multifocal inoculations of Walker 256 tumor. Brasil J Med Biol Res 33:815-822, 2000.
23. Rubin H. Systemic effects of cancer: role ofmultiple proteases and their toxic peptide products. Med Sci Monit 11:221-228, 2005.
24. Moraes SP, Cunha A, Neto JAR, Barbosa H, Roncolatto CAP, Duarte RF. Modelo experimental de tumor de Walker. Acta Cir Bras 15:10, 2000.
25. Wasser SP. Review of medicinal mushrooms advances: good news from old allies. Herbal Gram 56:28-33, 2002.
26. Lull C, Wichers HJ, Savelkoul FJ. Antiinflammatory and immunomod- ulating properties of fungal metabolites. Mediators Inflamm 9:63-80, 2005.
27. Fortes RC, Taveira VC, Novaes MRCG. The immunomodulator role of | -D-glucans as co-adjuvant for cancer therapy. Rev Bras Nutr Clin 21: 163-168, 2006.
28. Lindequist U, Niedermeyer THJ, Jiilich WD. Pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2:285-299, 2005.
29. Salven P, Orpana A, Joeensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5:487-491, 1999.
30. Georgilis K, Athanassiades P. Leukocytosis associated with localized bladder cancer: resolution with radiation therapy. J Urol 161:1567, 1999.
31. Desmeules S, Levesque R, Jaussent I, Leray-Moragues H, Chalabi L, Canaud B. Creatinine index and lean body mass are excellent predictors of long-term survival in haemodiafiltration patients. Nephrol Dial Transplant 19:1182-1189, 2004.
32. Kuroiwa Y, Nishikawa A, Imazawa T, Kanki K, Kitamura Y, Umemura T, Hirose M. Lack of subchronic toxicity of an aqueous extract of Agaricus blazei Murril in F344 rats. Food Chem Toxicol 43:1047-1053, 2005.
33. Shevde LA, Joshi NN, Shinde SR, Nadikarni J. Studies of functional status of circulating lymphocytes in unaffected members from cancer families. Hum Immunol 59:373-381, 1998.
34. Batra RK, Lin Y, Sharma S, Dohadwala M, Luo J, Pold M, Dubinett SM. Non-small cell lung cancer derived soluble mediators enhance apoptosis in activated T-lymphocytes through an IkB kinase-dependent mechanism. Cancer Res 63:642-646, 2003.
35. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T-lymphocytes subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 3755-3762, 2004.
36. McArdle PA, McMillan DC, Wallace AM, Underwood MA. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. Br J Cancer 91:1755-1757, 2004.
37. Lai HS, Lee JC, Lee PH, Whang ST, Chen WJ. Plasma free amino acid profile in cancer patients. Semin Cancer Biol 15:267-276, 2005.
38. Soeters PB, Poll MCG, Gemert WG, Dejong CHC. Amino acid adequacy and pathophysiological states. J Nutr 134:1575S-1582S, 2004.
39. Sarhill N, Mahmoud FA, Christie R, Tahir A. Assessment of nutritional status and fluid deficits in advanced cancer. Am J Hosp Palliat Care 20: 465-473, 2003.
40. Harada T, Masuda S, Arii M, Adashi Y, Nakajima M, Yadomae T, Ohno N. Soy isoflavone a glycone modulates a hematopoietic response in combination with soluble | -glucan: SCG. Biol Pharm Bull 28:2342-2345, 2005.
41. Younes RN, Noguchi Y. Pathophysiology of cancer cachexia. Rev Hosp Clin Fac Med Sao Paulo 55:181-193, 2000.
42. Maritess C, Small S, Waltz-Hill M. Alternative nutrition therapies in cancer patients. Semin Oncol Nurs 21:173-176, 2005.
43. Schueren MAEB. Nutritional support strategies for malnourished cancer patients. Eur J Oncol Nurs 9:S78-S89, 2005.